Nguyen Phuc Huynh, Nguyen Mai Truc Thi, Nguyen Xuan Thanh Thi, Ngo Thuan Tri, Vu Thu Viet Thi, Duong Tram Viet, Trinh Trang Xuan, Duong Huong Viet Nguyen
University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
Sai Gon Vinh Eye Hospital, Nghe An, Vietnam.
Int Ophthalmol. 2024 Dec 14;45(1):9. doi: 10.1007/s10792-024-03375-4.
The increasing drug resistance of Pseudomonas aeruginosa (PA) poses a serious challenge to the current treatment. Antibiograms of this pathogen often take 3-5 days, and treatment of Pseudomonas aeruginosa keratitis (PAK) is mainly based on preliminary physical examination, clinical experience, and medical guidelines. Pertinent clinical data on the causative agent and antibiotics for high efficacy are essential for early recognition and subsequent treatment.
To report the etiology, risk factors, treatment outcomes, antibiotic susceptibilities, and trends of PAK.
This retrospective study included culture-proven PAK cases at the Ho Chi Minh City Eye Hospital Cornea Department between January 2018 and December 2022. Culture results showing coinfection were excluded from the study.
Among 154 eyes infected by PA (n = 154) of 154 patients, ocular trauma was the leading risk factor (53.2%); only 16 patients had contact lenses (10.4%). Among the 154 eyes, 102/154 required surgical intervention (66.2%); and 31/154 eyes required evisceration (20.1%). PA was sensitive to tobramycin (95.9%), ciprofloxacin (91.9%), levofloxacin (91.9%), ofloxacin (87.4%), and moxifloxacin (20.0%). The prevalence of multidrug resistance (MDR) was 31.8%, and extensive drug resistance (XDR) was 3.9%. Poor outcomes (need for surgical intervention or final visual acuity ≤ CF 3 m) included age > 50 years, ocular surface diseases, deep infiltrate, large infiltrate size ≥ 5 mm, and ring infiltrate (p < 0.05).
PAK, which is associated with increasing drug resistance, poses significant challenges in terms of treatment, with 66.2% of patients requiring surgical intervention. With the rapid progression of PAK, early treatment with broad-spectrum and effective antibiotics is necessary. However, future research should focus on new methods to enhance treatment effectiveness.
铜绿假单胞菌(PA)耐药性不断增加,给当前治疗带来严峻挑战。该病原体的药敏试验通常需要3至5天,而铜绿假单胞菌性角膜炎(PAK)的治疗主要基于初步体格检查、临床经验和医学指南。有关病原体及高效抗生素的相关临床数据对于早期识别和后续治疗至关重要。
报告PAK的病因、危险因素、治疗结果、抗生素敏感性及趋势。
本回顾性研究纳入了2018年1月至2022年12月期间胡志明市眼科医院角膜科经培养证实的PAK病例。研究排除了显示合并感染的培养结果。
在154例患者的154只感染PA的眼中(n = 154),眼外伤是主要危险因素(53.2%);仅有16例患者佩戴隐形眼镜(10.4%)。在这154只眼中,102/154只需要手术干预(66.2%);31/154只眼需要眼球摘除术(20.1%)。PA对妥布霉素敏感(95.9%)、环丙沙星(91.9%)、左氧氟沙星(91.9%)、氧氟沙星(87.4%)和莫西沙星(20.0%)。多重耐药(MDR)的患病率为31.8%,广泛耐药(XDR)为3.9%。预后不良(需要手术干预或最终视力≤CF 3米)包括年龄>50岁、眼表疾病、深层浸润、浸润灶大小≥5毫米及环形浸润(p < 0.05)。
PAK与耐药性增加相关,在治疗方面构成重大挑战,66.2%的患者需要手术干预。鉴于PAK进展迅速,有必要尽早使用广谱有效抗生素进行治疗。然而,未来研究应聚焦于提高治疗效果的新方法。